Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study

BACKGROUND: For patients who have contraindications to or have failed checkpoint inhibitors, chemotherapy remains the standard second-line option to treat non-oncogene-addicted advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of S-1-based non-plati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiangling, Wang, Ting, Chu, Yunxia, Liu, Jie, Yi, Cuihua, Yu, Xuejun, Wang, Yonggang, Zheng, Tianying, Cao, Fangli, Qu, Linli, Yu, Bo, Liu, Huayong, Ding, Fei, Wang, Shuang, Wang, Xiangbo, Hao, Jing, Wang, Xiuwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061129/
https://www.ncbi.nlm.nih.gov/pubmed/37007066
http://dx.doi.org/10.3389/fonc.2023.1089234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061129/
https://www.ncbi.nlm.nih.gov/pubmed/37007066
http://dx.doi.org/10.3389/fonc.2023.1089234

Ejemplares similares